Physician profile
Alyssa S Daniel
NPI 1013233352
$3,297.17
in general payments reported to CMS, 2019-2025
20 companies · $562 in 2025
The $562 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $346 · 2023: $1,006 · 2024: $1,279 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,647 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,646.84 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $645.15 | 2022-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $558.58 | 2021-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $474.00 | 2024 | Zoryve |
| Lilly USA, LLC | $284.38 | 2022-2025 | Ebglyss, Olumiant, Taltz |
| E.R. Squibb & Sons, L.L.C. | $210.64 | 2023-2024 | Sotyktu |
| Dermavant Sciences, INC. | $186.28 | 2023-2024 | Vtama |
| Genzyme Corporation | $158.34 | 2022-2025 | |
| Ucb, INC. | $108.52 | 2024 | Bimzelx |
| Hill Dermaceuticals, INC. | $108.19 | 2023 | Tolak |
| Janssen Scientific Affairs, LLC | $96.57 | 2022 | |
| Sun Pharmaceutical Industries INC. | $94.67 | 2025 | |
| Pfizer INC. | $92.94 | 2023-2025 | |
| Incyte Corporation | $67.53 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $42.07 | 2025 | |
| Galderma Laboratories, L.P. | $38.49 | 2021-2025 | Nemluvio |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $37.68 | 2023-2024 | Libtayo, Dupixent |
| Leo Pharma INC. | $33.42 | 2022-2023 | Adbry |
| Amgen INC. | $26.31 | 2024 | Otezla |
| Merz North America, INC. | $24.72 | 2023 | Xeomin |
| Organon LLC | $8.69 | 2025 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.